We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Tern Plc | TERN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.20 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
| Industry Sector |
|---|
| SOFTWARE & COMPUTER SERVICES |
| Top Posts |
|---|
Posted at 19/3/2025 13:25 by steveberyl USA Investors will see this opportunity FIRST and pile in. |
Posted at 10/3/2025 20:00 by superscrew133 Nice readingTalking Medicines has taken a high-profile residency in Silicon Valley as part of the Scottish Government/SDI Market Booster Program, marking a significant step in accelerating our US growth. This initiative places us at the heart of the world’s leading tech and innovation hub, allowing us to deepen our engagement with industry pioneers and expand our reach within the US healthcare ecosystem. After our first week in the Valley, here are some of the most common questions I’ve been asked—and my reflections on what this expansion means for Talking Medicines. 1. What motivated Talking Medicines to expand into the US market? The US is the global leader in the pharmaceutical industry, making it a natural next step for our growth. We’ve already established a legal entity and headquarters in New York, bringing us closer to our customer base. Now, having successfully built our East Coast foundations, we’re looking westward—to Silicon Valley—to explore further opportunities, connect with tech leaders, and engage with new customers in the region. 2. How does Silicon Valley’s ecosystem align with Talking Medicines’ objectives? Silicon Valley is a powerhouse for AI, data science, and innovation—the very core of what we do. Our US Market Booster residency is a strategic move to accelerate collaboration with leading tech innovators, enhance our patient-centric AI solutions, and explore new frontiers in health and wellness intelligence. The Valley offers a unique environment to scale our impact and connect with global thought leaders who are shaping the future of AI-driven healthcare. 3. What challenges do you anticipate in the US healthcare landscape? The complexity of the US healthcare system presents both challenges and opportunities. At Talking Medicines, we bring deep expertise in navigating regulatory frameworks, understanding diverse HCP (healthcare professional) and patient demographics, and implementing structured processes to deliver actionable intelligence. These challenges also fuel innovation, allowing us to refine and adapt our solutions to meet the unique needs of the US market. 4. How does Talking Medicines differentiate itself from competitors? What sets us apart is our ability to translate HCP and patient experiences into real-world intelligence for pharmaceutical marketers and agency strategists. By harnessing Advanced Data Science and AI, we provide unparalleled insights into patient and HCP sentiment—ulti 5. What are your immediate goals during this Silicon Valley tenure? We have three key objectives for our time in Silicon Valley: Forge strategic partnerships with tech and healthcare leaders. Attract top US-based talent to strengthen our expertise. Engage with investors who share our vision for transforming pharmaceutical marketing through AI-driven insights. Being in the Valley allows us to stay at the cutting edge of AI and healthcare innovation, ensuring that our solutions continue to lead in the industry. 6. How do you envision the future of Talking Medicines in the US? Our vision is to be an integral part of the US healthcare ecosystem, providing pharma with the most advanced AI-powered intelligence tools to better understand and engage with HCPs and patients. By bridging the gap between real-world experiences and pharma decision-making, we aim to improve patient outcomes and contribute to a more patient-centered healthcare system. Let’s Connect This week has reinforced the scale of the opportunity ahead and our commitment to driving innovation at the intersection of AI and healthcare. We’re actively meeting with partners, investors, and industry leaders—if you’d like to connect, please reach out to: 📩 jo@talkingmedicines. Jo Halliday (CEO), Scott Crae (Partnerships), and Elizabeth Fairley (CDO/COO) are available for meetings—let&# ← Previous Blog |
Posted at 28/2/2025 19:41 by tullynessle I have deleted post 361461.IMO TERN Shareholders should take confidence from the Institutional Co-Investors, DA Employees, DA private investors and private investors common to DA & Tern; who are listed at the Device Authority "Confirmation Statement" dated 21 February, 2024. All of us have an interest in the success of Device Authority - albeit that some are better informed than others. I have a great interest in Device Authority (through TERN) and am proud of the progress that a British Company is achieving alongside its partner USA / Global behemoths. Companies House - Device Authority [28 Feb 2024 Confirmation statement made on 21 February 2024 with updates View PDF Confirmation statement made on 21 February 2024 with updates - link opens in a new window - 9 pages) |
Posted at 22/2/2025 11:21 by moneymaker617 I would agree with part of that .. older directors despite their acquired knowledge and notable historical successes often look to create opportunities to see them thro to retirement (the gravy train) .. however Tern’s primary investment’s are backed by notable industry specialists and investors who see potential and who will have conducted extensive due diligence before committing funds which should be reassurance for investors here .. realisations will happen not because of Tern but because those external investors will require a significant ROI to which Tern holders’ will eventually benefit from .. nai |
Posted at 10/2/2025 11:10 by jonc Where are ebumbers/investor125 |
Posted at 06/2/2025 09:28 by bingoprize What Deepseek does highlight in a roundabout way is that’s all the market has to go on. Same as DA no progressive official updates for investors to speculate on. As seed investors Tern must of been excited about the market potential and how these fledgling companies can exploit them. Because Tern are seed investors it’s in their hands to keep communicating that potential and asset progression in successfully travelling that foreseen road. That builds faith in asset selection and Terns abilities as a company capable of achieving its crystal ball visions. I don’t see why they have cornered themselves in this needless none positive no action. It doesn’t need to be RNS’s all the time. Just don’t be silent, congratulate companies on baby steps, note the progress. Build the Tern connections, build the Tern brand. It’s basic PR. |
Posted at 28/1/2025 08:58 by eeezeeetiger Market Makers or Manipulators as I like to call them have been playing games to help suppress the share price aided by the trolls on the LSE & ADVFN chat boards. Tom & his mates lost a few quid on this over a decade ago & have seemingly held a grudge against Tern ever since to the point where Tern tried legally pursuing Tom & his cronies for harassment if memory serves. I recall one early investor here posting the details and the background to explain the historic bad feeling Tom has for Tern.Troll activity has increased to attempt to unnerve investors to cause them to sell into any rise. Most of the investors who have been here many years understand this so the trolls look to target new posters on this BB. Context is important. |
Posted at 24/1/2025 07:59 by investor125 Good morning LTHs.Quick reminder...INVESTORS CHRONICLE has set a target price for TERN PLC of 22p this year...BEFORE our Chairman confirmed that on a substantial exit all holders WILL receive a SPECIAL DIVIDEND. All serious investors should ignore as always the well known shorters led by Tommmy. |
Posted at 08/1/2025 16:16 by stentorian DA has, effectively, been taken over by investors who are predominently ex-GCHQ (Albany/1011 Ventures). I can foresee a deal where KeyScaler is adopted by "UK plc" on the say so of GCHQ. Imagine assets in NHS/Army/Navy/RAF/HMThese investors have been let in by Sisto and Leith at a very cheap price (don't forget these two bought into DA directly at the same time). There had better be method in their madness. I wish they would get a move on! |
Posted at 12/12/2024 15:03 by tullynessle Pitchbook / CalabrioCalabrio is a Private Company with 559 employees. One of its investors is Thoma Bravo Extract "Who are Calabrio’s investors? Thoma Bravo, Golub Capital, AI Venture Labs, and New Mountain Capital have invested in Calabrio." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
